# The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers

Study · id `cardio:ct-nct01108120` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01108120](<https://clinicaltrials.gov/study/NCT01108120>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01108120

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT01108120. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2022-12-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT01108120, source copy `cardio:ctgov-nct01108120-2023-09-28`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01108120, source copy `cardio:ctgov-nct01108120-2023-09-28`, retrieved 2026-10-26)
- Primary completion: 2022-12-30 (actual) (ClinicalTrials.gov record NCT01108120, source copy `cardio:ctgov-nct01108120-2023-09-28`, retrieved 2026-10-26)
- Completion: 2022-12-30 (actual) (ClinicalTrials.gov record NCT01108120, source copy `cardio:ctgov-nct01108120-2023-09-28`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01108120, source copy `cardio:ctgov-nct01108120-2023-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01108120-2023-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers
- Condition: Diabetic Foot Ulcer
- Intervention (Drug): continuous intra-femoral thrombolysis group
- Intervention (Drug): Conventional therapy group
- Lead sponsor: Xiang Guang-da
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Xiang Guang-da (`cardio:org-xiang-guang-da`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Continuous intrafemoral artery infusion of urokinase improves diabetic foot ulcers healing and decreases cardiovascular events in a long-term follow-up study (`cardio:pubmed-38216296`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b8fe614569863b864e774b04f5ee4706bf0428d17830cb942753495ff7cc8552
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
